Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor Mobilization in Sickle Cell Disease
NCT02193191Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2014
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plerixafor in sickle cell disease (SCD), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Safety at 30 days and Efficacy (CD34+ Mobilization). Started Sep 2014; status: completed.
02
Drugs
plerixafor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02193191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193191.